A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 320 participants.
Also called NCT01473420
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 320 participants
- Registry
-
NCT01473420
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01473420. Randomized; quadruple masking; primary purpose treatment. Start 2012-01-17 (actual); primary completion 2014-02-28 (actual). Results posted on 2018-06-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
- Acronym
- AiME - 13
- Condition
- Chronic Renal Failure
- Condition
- Chronic Kidney Disease
- Intervention (Biological)
- Epoetin Hospira
- Intervention (Biological)
- Epogen Amgen
- Lead sponsor
- Pfizer
- Collaborator
- Hospira, now a wholly owned subsidiary of Pfizer
Record details
- Record id
cardio:ct-nct01473420- Content hash
9d128ad0f9d000d9936ee04f61706b134e561eadcec77d0a2b28cdd1aa7a20b9